@article{3139625,
    title = "Search for potential markers for prostate cancer diagnosis, prognosis
and treatment in clinical tissue specimens using amine-specific isobaric
tagging (iTRAQ) with two-dimensional liquid chromatography and tandem
mass spectrometry",
    author = "Garbis, Spiros D. and Tyritzis, Stavros I. and Roumeliotis, Theodoros and and Zerefos, Panagiotis and Giannopoulou, Eugenia G. and Vlahou, Antonia and and Kossida, Sophia and Diaz, Jose and Vourekas, Stavros and and Tamvakopoulos, Constantin and Pavlakis, Kitty and Sanoudou, Despina and and Constantinides, Constantinos A.",
    journal = "Journal of Proteome Research",
    year = "2008",
    volume = "7",
    number = "8",
    pages = "3146-3158",
    publisher = "AMER CHEMICAL SOC",
    issn = "1535-3893, 1535-3907",
    doi = "10.1021/pr800060r",
    keywords = "prostate cancer; proteomics; biomarkers; iTRAQ; LC-MS",
    abstract = "This study aimed to identify candidate new diagnosis and prognosis
markers and medicinal targets of prostate cancer (PCa), using state of
the art proteomics. A total of 20 prostate tissue specimens from 10
patients with benign prostatic hyperplasia (BPH) and 10 with PCa (Tumour
Node Metastasis [TNM] stage T1-T3) were analyzed by isobaric stable
isotope labeling (iTRAQ) and two-dimensional liquid
chromatography-tandem mass spectrometry (2DLC-MS/MS) approaches using a
hybrid quadrupole time-of-flight system (QqTOF). The study resulted in
the reproducible identification of 825 nonredundant gene products (p <=
0.05) of which 30 exhibited up-regulation (>= 2-fold) and another 35
exhibited downregulation (<= 0.5-fold) between the BPH and PCa specimens
constituting a major contribution toward their global proteomic
assessment. Selected findings were confirmed by immunohistochemical
analysis of prostate tissue specimens. The proteins determined support
existing knowledge and uncover novel and promising PCa biomarkers. The
PCa proteome found can serve as a useful aid for the identification of
improved diagnostic and prognostic markers and ultimately novel
chemopreventive and therapeutic targets."
}